Moritz Beissenhirtz

Moritz Beissenhirtz is an experienced investment director specializing in life sciences, currently serving at Brandenburg Kapital GmbH since July 2023. Concurrently, Moritz is a member of the advisory board for Kupando GmbH, a German biopharmaceutical company focused on developing innovative immunotherapies for cancer patients. Previous roles include project manager in business development at Sartorius, and participation in new business development at Thermo Fisher Scientific. Moritz has extensive experience from Mologen AG in business development and IP management, alongside roles as a senior patent analyst at IP Bewertungs AG and postdoctoral positions at The Hebrew University of Jerusalem and the University of Potsdam. Moritz holds a Ph.D. in Biochemistry from the University of Potsdam and has completed lab work at the Università degli Studi di Firenze and The Hong Kong University of Science and Technology.